In this issue
Real-world SEER registry analyses presented at ACMS and ASCO 2026 highlight how 31-GEP molecular testing identifies patients with early-stage and node-negative melanoma at higher risk of death.
Rate this content's potential impact on patient outcomes
Average rating 0 / 5. Vote count: 0
No votes so far! Be the first to rate this content.
Latest articles
All articles


We’ve noticed you’re accessing
from North/South America.
from North/South America.